josh hardman
LightNews LightNews
banner
josh-hardman.bsky.social
josh hardman
@josh-hardman.bsky.social
1.2K followers 230 following 370 posts
full of microplastics and writing about psychedelics at psychedelicalpha.com ( @psychedelicalpha.bsky.social )
Posts Replies Media Videos
Pinned
josh-hardman.bsky.social
josh hardman @josh-hardman.bsky.social · Nov 15
I have started a 'Psychedelics Starter Pack' of Bluesky accounts related to the field.

It's very much a Work In Progress - please reply or DM with suggestions.

go.bsky.app/VNupHtA
josh-hardman.bsky.social
Psychedelic Bulletin 214:

- Largest LSD Microdosing Trial Fails Across All Endpoints

- AtaiBeckley’s Phase 2b Debrief

- UK Gov. Holds Line on Psilocybin Despite MPs' Written Questions

- MAHA Summit ft. Psychedelics

- VA's Ph 3 Psilocybin Study

- More...

psychedelicalpha.com/news/p%ce%b1...
Pα+ Psychedelic Bulletin #214: LSD Microdosing Program Collapses; AtaiBeckley’s Phase 2b Debrief; UK Government Responds to MPs’ Psilocybin-Related Questions - Psychedelic Alpha
Largest LSD Microdosing Trial to Date Fails Across All Endpoints • AtaiBeckley’s Phase 2b Debrief: More Detail on SAE and Phase 3 Considerations • UK Government Holds Line on Psilocybin Despite New…
psychedelicalpha.com
November 19, 2025 at 3:54 PM
josh-hardman.bsky.social
Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action

psychedelicalpha.com/news/beyond-...
Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action - Psychedelic Alpha
In this interview with Psychedelic Alpha’s Josh Hardman, psychiatrist, therapist and researcher Dr. Óscar Soto discusses psychedelic trial design, therapeutic fidelity, and the evolving role of…
psychedelicalpha.com
November 14, 2025 at 3:38 PM
josh-hardman.bsky.social
AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

We reviewed the readout and spoke with AtaiBeckley ( $ATAI ) CEO, Srinivas Rao, to dive deeper…

psychedelicalpha.com/news/ataibec...
AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3 - Psychedelic Alpha
This morning, AtaiBeckley shared positive topline data from the open-label portion of its Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) in patients with treatment-resistant depression (TRD)…
psychedelicalpha.com
November 10, 2025 at 12:02 PM
josh-hardman.bsky.social
Psychedelic Bulletin 213

- Compass Accelerates Psilocybin Launch Plans by Almost a Year

- Australia’s VA Will Fund Psychedelic-Assisted Psychotherapy for Veterans

- AbbVie Paid $900M Upfront for Gilgamesh’s Psychedelic Candidate

psychedelicalpha.com/news/p%ce%b1...
Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate - Psychedelic A...
Compass Accelerates Psilocybin Launch Plans by Almost a Year • Australia’s VA Will Fund Psychedelic-Assisted Psychotherapy for Veterans • AbbVie Paid $900M Upfront for Gilgamesh’s Psychedelic Candidat...
psychedelicalpha.com
November 7, 2025 at 3:36 PM
josh-hardman.bsky.social
BREAKING: Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

More detail, including interview with $CMPS CEO Kabir Nath, in our coverage...

psychedelicalpha.com/news/compass...
Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months - Psychedelic Alpha
This morning, Compass Pathways announced that it is preparing to launch its psilocybin therapy (COMP360) for treatment-resistant depression (TRD) at least nine months earlier than previously planned…
psychedelicalpha.com
November 4, 2025 at 11:50 AM
josh-hardman.bsky.social
Pα+ Psychedelic Bulletin 212

- Delix Posts Early Efficacy Signal for ‘Non-Hallucinogenic’ Neuroplastogen as FDA Clears At-Home Phase II

- NRx Wants FDA to Ban Its Competitors’ Ketamine

- Cybin Trades Toxic Financing for Top Tier Investors in $175M Raise

psychedelicalpha.com/news/p%ce%b1...
Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M - Psychedelic Alpha
Delix Therapeutics Posts Early Efficacy Signal for ‘Non-Hallucinogenic’ Neuroplastogen as FDA Clears At-Home Phase II • NRx Pharmaceuticals Wants FDA to Ban Its Competitors’ Ketamine •
psychedelicalpha.com
October 31, 2025 at 3:40 PM
josh-hardman.bsky.social
Q3’25 Psychedelic Lobbying Update

Here, we share our analysis of the latest developments in federal psychedelics lobbying for our Pα+ subscribers.

Here’s a review of Q3 2025 activity…

psychedelicalpha.com/news/q325-ps...
Q3’25 Psychedelic Lobbying Update - Psychedelic Alpha
Each quarter, we provide a look at federal lobbying disclosures by psychedelic drug developers and nonprofits. Here, we share our analysis of the latest developments for our Pα+ subscribers.
psychedelicalpha.com
October 29, 2025 at 1:38 PM
josh-hardman.bsky.social
Pα+ Psychedelic Bulletin #211:

- AbbVie Officially Enters Psychedelics

- atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation

- California Bill Signed

- No Commissioner's National Priority Voucher for Psychedelics

- and more...

psychedelicalpha.com/news/p%ce%b1...
Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; FDA Gives atai-Beckley’s 5-MeO-DMT Breakthrough Therapy Status; Newsom Signs Psychedelics Bill; No Priority Vouchers for Psychedel...
AbbVie Officially Enters Psychedelics as Gilgamesh Deal Closes, Patent Dispute Opens • BPL-003 Wins Breakthrough Status as atai Raises $150M • FDA Passes on Psychedelics in First Round of Priority Vou...
psychedelicalpha.com
October 24, 2025 at 2:15 PM
josh-hardman.bsky.social
A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research Agenda

I speak with Schoevers, psychiatrist & epidemiologist who is, among other things, PI of PsyPal, a large, EU-funded study of psilocybin in patients w/ palliative care needs

psychedelicalpha.com/news/a-europ...
A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research Agenda - Psychedelic Alpha
Psychedelic Alpha’s Josh Hardman speaks with Robert Schoevers, Head of Psychiatry at University Medical Center Groningen and principal investigator of the EU-funded PsyPal study, about growing public ...
psychedelicalpha.com
October 22, 2025 at 1:42 PM
Reposted by josh hardman
kangaslampi.bsky.social
Had a chat with @josh-hardman.bsky.social of @psychedelicalpha.bsky.social recently about recovered memories under #psychedelics. psychedelicalpha.com/news/recover...
Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall - Psychedelic Alpha
Psychedelic Alpha’s Josh Hardman speaks with clinical psychologist and trauma researcher Dr. Samuli Kangaslampi about how psychedelics affect autobiographical memory. They discuss the historical…
psychedelicalpha.com
October 15, 2025 at 4:13 AM
josh-hardman.bsky.social
Today, we launch The Psychedelic Practitioner by Psychedelic Alpha

It’s designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.

Read now: psychedelicalpha.com/news/the-psy...
The Psychedelic Practitioner: Issue 1 - Psychedelic Alpha
Welcome to the inaugural issue of The Psychedelic Practitioner, a new publication for the evolving practice of psychedelic care.
psychedelicalpha.com
October 9, 2025 at 2:31 PM
josh-hardman.bsky.social
Q3 2025 Psychedelic Investor Survey Results

Today, we share topline results from the latest in our series of psychedelics investor surveys.

Explore: psychedelicalpha.com/news/psyched...
October 7, 2025 at 10:44 AM
josh-hardman.bsky.social
The Psychedelic News Feed: Sept 29 - Oct 5, 2025

psychedelicalpha.com/news/the-psy...
The Psychedelic News Feed: Sept 29 - Oct 5, 2025 - Psychedelic Alpha
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing September 29, 2025.
psychedelicalpha.com
October 6, 2025 at 12:46 PM
josh-hardman.bsky.social
Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study

We speak to researchers and take a deeper dive into the published study, with a focus on dose-response, safety, and MindMed's eschewing of psychotherapy.

psychedelicalpha.com/news/breakth...
Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study - Psychedelic Alpha
MindMed’s Phase 2b LSD (MM120) for generalised anxiety disorder (GAD) study, published in JAMA earlier this month, shows promising efficacy and a favourable safety profile. Here…
psychedelicalpha.com
September 22, 2025 at 3:42 PM
josh-hardman.bsky.social
UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

This morning, the UK's professional body for psychiatrists published a Position Statement and Guidance Booklet on the use of psychedelics.

psychedelicalpha.com/news/uk-roya...
UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence - Psychedelic Alpha
This morning, the UK’s Royal College of Psychiatrists published a Position Statement on psychedelics and related substances for medical use. Here, we briefly unpack the statement, as well as related…
psychedelicalpha.com
September 19, 2025 at 8:48 AM
josh-hardman.bsky.social
🎯 Our signature Bullseye chart has just been refreshed, mapping the global pipeline of psychedelic drug candidates, from discovery through to (potential) approval.

Explore the latest Bullseye Charts + the full live Tracker now: psychedelicalpha.com/news/q325-ps...
Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts - Psychedelic Alpha
We present the psychedelic drug development pipeline in two ‘bullseye chart’ formats, as of Q3’2025.
psychedelicalpha.com
September 16, 2025 at 11:43 AM
josh-hardman.bsky.social
From the EMA to Gustave Roussy, Dr. Florence Butlen-Ducuing has witnessed Europe’s psychedelic renaissance first-hand.

I sat down with her to discuss.

psychedelicalpha.com/news/no-prej...
‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance - Psychedelic Alpha
From a long stint at the European Medicines Agency’s (EMA) Office of Therapies for Neurological and Psychiatric Disorders to her present-day practice as a clinical psychiatrist at leading cancer…
psychedelicalpha.com
September 11, 2025 at 2:33 PM
josh-hardman.bsky.social
On Thursday, we broke the news that FDA had published the Complete Response Letter (CRL) it sent to Lykos Therapeutics 13 months ago today, when it rejected its MDMA for PTSD new drug application.

Today, we take a much closer (~5,000 word) look...

More: psychedelicalpha.com/news/unpacki...
Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos - Psychedelic Alpha
Last Thursday, FDA published the complete response letter (CRL) it sent to Lykos Therapeutics last year, when it rejected its MDMA for PTSD new drug application. Here, we take a closer look at the…
psychedelicalpha.com
September 8, 2025 at 11:32 AM
josh-hardman.bsky.social
BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

psychedelicalpha.com/news/breakin...
BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha
FDA has published its complete response letter (CRL) to Lykos Therapeutics, citing durability, safety, and bias concerns in rejecting MDMA therapy for PTSD. Here, we very briefly unpack the letter.
psychedelicalpha.com
September 4, 2025 at 4:35 PM
josh-hardman.bsky.social
Pα+ Psychedelic Bulletin #207

- Lykos Rebrands to Resilient

- Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision

- AbbVie-Gilgamesh Deal Viewed as Validation

- Psilocybin Rescheduling Petition Heads to HHS

- Much, much more...

psychedelicalpha.com/news/p%ce%b1...
Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation - Psychedelic Alpha
Lykos Therapeutics Rebrands to Resilient Pharmaceuticals • Pharma Pushes Back on Norway’s Off-Label Ketamine Decision • AbbVie–Gilgamesh Deal Viewed as Validation for Short-Acting Psychedelics •
psychedelicalpha.com
August 28, 2025 at 5:08 PM
josh-hardman.bsky.social
Another scoop today.

One of the world's best healthcare systems has decided to reimburse generic ketamine for treatment-resistant depression.

Note that J&J's Spravato (esketamine nasal spray) is not reimbursed for TRD in the Nordic country.

Big news...

psychedelicalpha.com/news/norway-...
Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression - Psychedelic Alpha
This morning, in a world-first move, Norwegian regulators approved national reimbursement for the off-label use of generic ketamine in treatment-resistant depression. Here, we break the news…
psychedelicalpha.com
August 25, 2025 at 9:04 AM
josh-hardman.bsky.social
July 2025 Psychedelic Patent Update

Explore our interactive database of psychedelic patent activity in July 2025 via our Pα+ interface. Plus, we look at how a new patent family provides a look at Rivo Bio.

psychedelicalpha.com/news/july-20...
July 2025 Psychedelic Patent Update - Psychedelic Alpha
Explore our interactive database of psychedelic patent activity in July 2025 via our Pα+ interface. Plus, we look at how a new patent family provides a look at Rivo Bio.
psychedelicalpha.com
August 23, 2025 at 2:55 PM
josh-hardman.bsky.social
Discover Psychedelic Alpha like never before by using our new AI search tool, trained exclusively on in-house content and data.

Use any search bar on our website to get started, or visit our dedicated webpage: psychedelicalpha.com/ai
August 20, 2025 at 11:43 AM
josh-hardman.bsky.social
BREAKING: Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression

Read our Deep Dive coverage, including a discussion with company management, now.

psychedelicalpha.com/news/reunion...
Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression - Psychedelic Alpha
This morning, Reunion Neuroscience posted positive topline results from its Phase 2 study of RE104, its 4-OH-DiPT prodrug, in postpartum depression (PPD). We spoke with Reunion leadership to dig deepe...
psychedelicalpha.com
August 18, 2025 at 11:48 AM
Reposted by josh hardman
sthom003.bsky.social
Fantastic discussion between two excellent psychedelic scientists, spanning the generations of research progress! It really should say Huxley to Hefter to Jaster! Well done @jasteralaina.bsky.social!
August 12, 2025 at 10:43 PM